Recombinant Clostridium difficile Toxin Fragments as Carrier Protein for PSII Surface Polysaccharide Preserve Their Neutralizing Activity

Clostridium difficile is a Gram-positive bacterium and is the most commonly diagnosed cause of hospital-associated and antimicrobial-associated diarrhea. Despite the emergence of epidemic C. difficile strains having led to an increase in the incidence of the disease, a vaccine against this pathogen is not currently available. C. difficile strains produce two main toxins (TcdA and TcdB) and express three highly complex cell-surface polysaccharides (PSI, PSII and PSIII). PSII is the more abundantly expressed by most C. difficile ribotypes offering the opportunity of the development of a carbohydrate-based vaccine. In this paper, we evaluate the efficacy, in naive mice model, of PSII glycoconjugates where recombinant toxins A and B fragments (TcdA_B2 and TcdB_GT respectively) have been used as carriers. Both glycoconjugates elicited IgG titers anti-PSII although only the TcdB_GT conjugate induced a response comparable to that obtained with CRM197. Moreover, TcdA_B2 and TcdB_GT conjugated to PSII retained the ability to elicit IgG with neutralizing activity against the respective toxins. These results are a crucial proof of concept for the development of glycoconjugate vaccines against C. difficile infection (CDI) that combine different C. difficile antigens to potentially prevent bacterial colonization of the gut and neutralize toxin activity.

[1]  M. Scarselli,et al.  Vaccination against Clostridium difficile using toxin fragments , 2014, Gut microbes.

[2]  R. Adamo,et al.  Recent mechanistic insights on glycoconjugate vaccines and future perspectives. , 2013, ACS chemical biology.

[3]  D. Gerding,et al.  Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. , 2013, JAMA internal medicine.

[4]  K. Jansen,et al.  A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile , 2013, Microbiology.

[5]  R. Rappuoli,et al.  Protective Efficacy Induced by Recombinant Clostridium difficile Toxin Fragments , 2013, Infection and Immunity.

[6]  M. Sagermann,et al.  Carbohydrate-based Clostridium difficile vaccines , 2013, Expert review of vaccines.

[7]  S. Tzipori,et al.  Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. , 2013, The Journal of infectious diseases.

[8]  D. Serruto,et al.  Multiple Factors Modulate Biofilm Formation by the Anaerobic Pathogen Clostridium difficile , 2012, Journal of bacteriology.

[9]  B. Kennedy,et al.  Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. , 2012, The Journal of infectious diseases.

[10]  D. Gerding,et al.  Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  R. Carman,et al.  A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. , 2012, Vaccine.

[12]  L. Lay,et al.  Phosphorylation of the synthetic hexasaccharide repeating unit is essential for the induction of antibodies to Clostridium difficile PSII cell wall polysaccharide. , 2012, ACS chemical biology.

[13]  M. Mallozzi,et al.  Clostridium difficile carbohydrates: glucan in spores, PSII common antigen in cells, immunogenicity of PSII in swine and synthesis of a dual C. difficile-ETEC conjugate vaccine. , 2012, Carbohydrate research.

[14]  J. Brisson,et al.  Structural characterization of surface glycans from Clostridium difficile. , 2012, Carbohydrate research.

[15]  M. Bachmann,et al.  Immunization strategies for Clostridium difficile infections , 2012, Expert review of vaccines.

[16]  R. Rappuoli,et al.  The design of semi-synthetic and synthetic glycoconjugate vaccines , 2011, Expert opinion on drug discovery.

[17]  R. Rappuoli,et al.  Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications. , 2011, Biologicals : journal of the International Association of Biological Standardization.

[18]  M. Oberli,et al.  A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic. , 2011, Chemistry & biology.

[19]  L. Lay,et al.  First synthesis of C. difficile PS-II cell wall polysaccharide repeating unit. , 2011, Organic letters.

[20]  Roger Baxter,et al.  Treatment with monoclonal antibodies against Clostridium difficile toxins. , 2010, The New England journal of medicine.

[21]  Roger Baxter,et al.  Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). , 2010, Vaccine.

[22]  Volker Brauer,et al.  Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels , 2009, Proceedings of the National Academy of Sciences.

[23]  C. Kelly,et al.  Clostridium difficile--more difficult than ever. , 2008, The New England journal of medicine.

[24]  J. Weese,et al.  Clostridium difficile cell-surface polysaccharides composed of pentaglycosyl and hexaglycosyl phosphate repeating units. , 2008, Carbohydrate research.

[25]  K. Aktories,et al.  Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. , 2007, Glycobiology.

[26]  T. Monath,et al.  Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. , 2005, Gastroenterology.

[27]  T. Monath,et al.  Clostridium difficile Vaccine and Serum Immunoglobulin G Antibody Response to Toxin A , 2003, Infection and Immunity.

[28]  C. Kelly,et al.  Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  T. Monath,et al.  Safety and Immunogenicity of Increasing Doses of aClostridium difficile Toxoid Vaccine Administered to Healthy Adults , 2001, Infection and Immunity.

[30]  C. Kelly,et al.  Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea , 2001, The Lancet.

[31]  G. Dougan,et al.  Immunogenicity of a Salmonella typhimurium aroA aroD Vaccine Expressing a Nontoxic Domain of Clostridium difficile Toxin A , 1999, Infection and Immunity.

[32]  S. Calderwood,et al.  Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain , 1997, Infection and immunity.